Industry news that matters to you.  Learn more

KineMed Announces Participation in a Global, Multi-Company Effort to Advance and Standardize a Diabetic Research Model

Reading time: 2 – 4 minutes

KineMed, Inc. announced participation in a global, two year, multi-organization effort to advance and standardize a single mouse model of early diabetic disease detection and progression. The two year effort brings together cutting edge expertise and technology with a goal to produce a new mouse research model system that can streamline the research and development of advances in diabetic research and improve the clinical success of programs using the model.

KineMed will contribute both biology expertise and kinetic biomarkers to provide feedback on the viability of the model systems and integration of rate based biomarkers into this next generation important tool.

This effort was conceived by TNO, an independent research organization whose expertise and research make an important contribution to the competitiveness of companies and organizations, to the economy and to the quality of society as a whole. The TNO-led consortium recently received the final approval from “The Netherlands Organization for Health Research and Development, “ZonMw” to start this challenging and promising project focusing on the early detection of the development of various diabetic complications in one single mouse model that closely mimics the human situation. This two-year project aims to deliver a predictive translational model in which the effect of potential new medicines can be evaluated at one early time point in disease development. This is a unique approach since normally for every diabetic complication a different animal model is used. This new approach should reduce time to market of potential new medicines and reduce the number of animals used in preclinical R&D

The development of new medicines requires significant time and effort for the evaluation of their safety, PK and efficacy. Within the ZonMw funded program ’More knowledge with less animals’ TNO has started a collaboration between the Netherlands-based academic centers University Medical Center Utrecht and the Radboud Proteomics Center, the Dutch companies BaseClear B.V. and Good Biomarker Sciences, Seventh Wave Laboratories, KineMed, Inc., etc.

The consortium will combine a large set of state-of-the-art technologies (such as ECM protein turnover analysis technology with deuterated water, transcriptomics by mRNAseq on a NextGen sequencer, proteomics profiling, histopathological and biomarker analyses in very small quantities of samples). It is this data integration and Systems Biology approach that will help us to find a set of markers (signatures) that predict the onset of multiple diabetic complications such as non-alcoholic steatohepatitis (NASH), diabetic nephropathy, atherosclerosis and retinopathy. The availability of such signatures thought to be a key in the early evaluation of efficacy and safety of new medicines.

The clinical translational expertise will be provided by clinicians from the Amsterdam Medical Center, Leiden University Medical Center, University Medical Center Utrecht and Erasmus Medical Center as well as providing access to biobank material, such as blood and organs.

TNO initiated this project and in addition to managing the project, they will provide their unique knowledge and expertise regarding metabolic disorders and system biology, including data integration.

Source: KineMed